Pharmaceuticals, Biotechnology and Life Sciences
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company…
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation…
French DBV Technologies has completed screening for the VITESSE phase 3 clinical trial In Q3 2024, exceeding its recruitment goal and successfully closed the screening process for the VITESSE Phase 3 study evaluating the Viaskin® Peanut Patch in peanut allergic children ages 4 – 7 years old.
BioVie, a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders,…
QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law…
EDMONTON, Alberta, Sept. 23, 2024 (GLOBE NEWSWIRE) — Life Sciences Week, Alberta’s flagship event for showcasing the life sciences sector,…
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS…
JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a…
Investor Webcast on Tuesday, September 24, 2024 at 8:30 a.m. ETSAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics…
MANKATO, Minn., Sept. 23, 2024 (GLOBE NEWSWIRE) — Digital Utilities Ventures, Inc. (OTC: DUTV), a leader in sustainable energy and…